PHIBRO ANIMAL HEALTH CORP (PAHC) research
PHIBRO ANIMAL HEALTH CORP- Sector
- Pharmaceuticals
- Last price
- $34.56
- As of
PHIBRO ANIMAL HEALTH CORP (PAHC): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-K filed 2026-08-26.
As of . Source: SEC EDGAR filings for PAHC. Method and limitations.
Share the PAHC intelligence card
See PAHC live in the terminal
Track PAHC's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live PAHC terminal, freeActive signals for PAHC
- highCONSENSUS_BUY
3 tracked funds increased PAHC this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +1578% to PAHC (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 83% of PAHC (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 69% of PAHC (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +222% to PAHC (2026Q2)
FREE, NO ACCOUNT
Every signal on PAHC, as it fires
You are seeing 5 of 20 signals recorded on PAHC since 2026-05-31.
The five above landed across 2 days. The other 15 were recorded on 4 other days. 14 of the 20 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PAHC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 71742Q106 · 2026Q2 | $29.4M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 71742Q106 · 2026Q2 | $15.1M | 0.02% | , |
| D. E. Shaw & Co., Inc.CUSIP 71742Q106 · 2026Q2 | $856K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 71742Q106 · 2026Q2 | $543K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 71742Q106 · 2026Q2 | $468K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PAHC
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PAHC against its peers
PAHC's operating margin of 12.8% ranks in the 66th percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | PAHC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.5B USD | 407M USD | 88 | 20 |
| Gross margin | 33.8% | 59.3% | 8 | 5 |
| Operating margin | 12.8% | -3.0% | 66 | 18 |
| Net margin | 6.6% | -5.4% | 73 | 19 |
| Return on equity | 25.9% | -21.3% | 98 | 22 |
| P / E | 14.2x | 14.3x | 50 | 8 |
Peers (25): INVA, OMER, XERS, ANRO, ANIP, ALMS, AMPH, PCRX, NUVB, TRVI, BHC, OCUL, NKTR, ESPR, SUPN, ACRS, HRMY, GPCR, COLL, OGN, AMLX, TARS, AVIR, BIOA, LQDA. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (PAHC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more PAHC signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PAHCand get the insider, 13F, options, and confluence read in one view.